<p>Oxaliplatin (4 mg/kg) was administered i.v. twice per week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22, and 23). Extended-release exenatide (100 μg/kg) was administered s.c. once per week for 9 weeks (days 1, 8, 15, 22, 29, 36, 43, 50, and 57). Oxaliplatin treatment ceased on day 23, however exenatide treatment was continued for an additional 5 weeks. (A) The von Frey test was performed before the first drug administration (on day 0) and on days 35, 42, 49, 56, and 63. Values are expressed as the mean ± standard error mean of five to six animals. (B) On days 42 and 63, the sciatic nerve was harvested, and samples were stained with toluidine blue. Images were captured at 800× magnification. Scale bar = 60 μm. (C) The area of axon (number of ...
AbstractOne form of neurotoxicity is the principal and dose-limiting toxicity of oxaliplatin. It has...
Purpose: This study analyzes the effect of oxaliplatin treatment on the facial nerve. The facial ner...
<p>C-26 cell-implanted mice were treated with oxaliplatin (6 mg/kg, i.p. days 1, 2, 8, and 9) and ex...
<p>Oxaliplatin (4 mg/kg) was administered i.v. twice per week for 4 weeks (days 1, 2, 8, 9, 15, 16, ...
<p>Cultured PC12 cells were incubated with oxaliplatin (3 μM) for 24 h in the presence or absence of...
Background Oxaliplatin has widely been used as a key drug in the treatment of colorectal cancer; how...
<p>5% dextrose (Cont), gemcitabine (100 mg/kg; Gem), and oxaliplatin (3 mg/kg; Oxal) were administer...
OBJECTIVE: Neurotoxicity is the most frequent dose-limiting side effect of the anti-cancer agent oxa...
Purpose: Oxaliplatin is a novel platinum compound with clinical activity in several malignancies. Ne...
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropath
<p>This top graph illustrates time-fluorescent uptake curves as percent change from baseline (t = 0 ...
BACKGROUND AND PURPOSE: The purpose of our study was to utilize a molecular imaging technology based...
The aim of this study was to determine the influence of oxaliplatin scheduling on the onset of perip...
BACKGROUND: Oxaliplatin, a platinum-based chemotherapy utilised in the treatment of colorectal cance...
<p>A) Refractoriness pre (black bars) and post (white bars) oxaliplatin treatment (Pre: 31.4±5.4%; P...
AbstractOne form of neurotoxicity is the principal and dose-limiting toxicity of oxaliplatin. It has...
Purpose: This study analyzes the effect of oxaliplatin treatment on the facial nerve. The facial ner...
<p>C-26 cell-implanted mice were treated with oxaliplatin (6 mg/kg, i.p. days 1, 2, 8, and 9) and ex...
<p>Oxaliplatin (4 mg/kg) was administered i.v. twice per week for 4 weeks (days 1, 2, 8, 9, 15, 16, ...
<p>Cultured PC12 cells were incubated with oxaliplatin (3 μM) for 24 h in the presence or absence of...
Background Oxaliplatin has widely been used as a key drug in the treatment of colorectal cancer; how...
<p>5% dextrose (Cont), gemcitabine (100 mg/kg; Gem), and oxaliplatin (3 mg/kg; Oxal) were administer...
OBJECTIVE: Neurotoxicity is the most frequent dose-limiting side effect of the anti-cancer agent oxa...
Purpose: Oxaliplatin is a novel platinum compound with clinical activity in several malignancies. Ne...
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropath
<p>This top graph illustrates time-fluorescent uptake curves as percent change from baseline (t = 0 ...
BACKGROUND AND PURPOSE: The purpose of our study was to utilize a molecular imaging technology based...
The aim of this study was to determine the influence of oxaliplatin scheduling on the onset of perip...
BACKGROUND: Oxaliplatin, a platinum-based chemotherapy utilised in the treatment of colorectal cance...
<p>A) Refractoriness pre (black bars) and post (white bars) oxaliplatin treatment (Pre: 31.4±5.4%; P...
AbstractOne form of neurotoxicity is the principal and dose-limiting toxicity of oxaliplatin. It has...
Purpose: This study analyzes the effect of oxaliplatin treatment on the facial nerve. The facial ner...
<p>C-26 cell-implanted mice were treated with oxaliplatin (6 mg/kg, i.p. days 1, 2, 8, and 9) and ex...